Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China
· Delayed Price · Currency is CNY 255.06
-3.44 (-1.33%)
At close: Mar 9, 2026
SHA:688506 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,520 | 5,821 | 560.42 | 701.83 | 794.95 | Upgrade
|
| Other Revenue | - | 1.67 | 1.46 | 1.45 | 1.78 | Upgrade
|
| Revenue | 2,520 | 5,823 | 561.87 | 703.28 | 796.73 | Upgrade
|
| Revenue Growth (YoY) | -56.72% | 936.31% | -20.11% | -11.73% | -21.33% | Upgrade
|
| Cost of Revenue | - | 283.74 | 242.26 | 237.7 | 203.39 | Upgrade
|
| Gross Profit | 2,520 | 5,539 | 319.61 | 465.58 | 593.34 | Upgrade
|
| Selling, General & Admin | - | 405.04 | 367.89 | 403.01 | 467.46 | Upgrade
|
| Research & Development | - | 1,443 | 746.23 | 375.02 | 278.6 | Upgrade
|
| Other Operating Expenses | 3,238 | 4.24 | -2.27 | 9.79 | 9.17 | Upgrade
|
| Operating Expenses | 3,238 | 1,853 | 1,105 | 795.41 | 752.86 | Upgrade
|
| Operating Income | -717.99 | 3,686 | -785.6 | -329.83 | -159.52 | Upgrade
|
| Interest Expense | - | -42.52 | -24.68 | -22.48 | -8.69 | Upgrade
|
| Interest & Investment Income | - | 225.32 | 5.71 | 0.77 | 3.61 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 63.88 | -1.11 | -0.05 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.12 | -3.38 | -0.84 | -0.56 | -0.35 | Upgrade
|
| EBT Excluding Unusual Items | -719.11 | 3,930 | -806.51 | -352.16 | -165.09 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 11.44 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.22 | -0.14 | -0.48 | -0.45 | Upgrade
|
| Other Unusual Items | - | 37.3 | 37.64 | 63.57 | 61.1 | Upgrade
|
| Pretax Income | -719.11 | 3,978 | -769.01 | -289.07 | -104.44 | Upgrade
|
| Income Tax Expense | 331.55 | 270.65 | 11.49 | -6.69 | -4.45 | Upgrade
|
| Earnings From Continuing Operations | -1,051 | 3,708 | -780.5 | -282.38 | -99.99 | Upgrade
|
| Net Income | -1,051 | 3,708 | -780.5 | -282.38 | -99.99 | Upgrade
|
| Net Income to Common | -1,051 | 3,708 | -780.5 | -282.38 | -99.99 | Upgrade
|
| Shares Outstanding (Basic) | 414 | 401 | 400 | 362 | 357 | Upgrade
|
| Shares Outstanding (Diluted) | 414 | 401 | 400 | 362 | 357 | Upgrade
|
| Shares Change (YoY) | 3.20% | 0.14% | 10.56% | 1.38% | 3.64% | Upgrade
|
| EPS (Basic) | -2.54 | 9.25 | -1.95 | -0.78 | -0.28 | Upgrade
|
| EPS (Diluted) | -2.54 | 9.25 | -1.95 | -0.78 | -0.28 | Upgrade
|
| Free Cash Flow | - | 3,975 | -697.29 | -293.21 | -179.63 | Upgrade
|
| Free Cash Flow Per Share | - | 9.92 | -1.74 | -0.81 | -0.50 | Upgrade
|
| Gross Margin | 100.00% | 95.13% | 56.88% | 66.20% | 74.47% | Upgrade
|
| Operating Margin | -28.49% | 63.31% | -139.82% | -46.90% | -20.02% | Upgrade
|
| Profit Margin | -41.69% | 63.67% | -138.91% | -40.15% | -12.55% | Upgrade
|
| Free Cash Flow Margin | - | 68.26% | -124.10% | -41.69% | -22.55% | Upgrade
|
| EBITDA | -650.09 | 3,754 | -727.25 | -272.27 | -109.37 | Upgrade
|
| EBITDA Margin | -25.80% | 64.48% | -129.43% | -38.71% | -13.73% | Upgrade
|
| D&A For EBITDA | 67.9 | 67.9 | 58.34 | 57.56 | 50.16 | Upgrade
|
| EBIT | -717.99 | 3,686 | -785.6 | -329.83 | -159.52 | Upgrade
|
| EBIT Margin | -28.49% | 63.31% | -139.82% | -46.90% | -20.02% | Upgrade
|
| Effective Tax Rate | - | 6.80% | - | - | - | Upgrade
|
| Revenue as Reported | - | 5,823 | 561.87 | 703.28 | 796.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.